IR
IART icon

Invictus RG’s Integra LifeSciences IART Stock Holding History

Invictus RG’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-322
Closed -$14K – 755
2016
Q4 		$14K Sell
322
-24
-7% -$976 0.01% 569
2016
Q3 		$14K Buy
346
+48
+16% +$2.01K 0.01% 624
2016
Q2 		$12K Buy
+298
New +$10.7K 0.01% 476

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invictus RG's IART Position: Q1 2017 in Review

Invictus RG sold out of Integra LifeSciences (IART) in Q1 2017, closing a stake of 322 shares — an estimated $14K sold.

Invictus RG first reported a position in IART in Q2 2016 and held it in 3 quarters. The position peaked at $14K in Q4 2016. 236 funds tracked by Wall St. Rank hold IART as of Q1 2017.

  • Invictus RG reported no remaining Integra LifeSciences position as of Q1 2017 after selling out during the quarter.
  • Invictus RG sold 322 Integra LifeSciences shares in Q1 2017, an estimated $14K.
  • Invictus RG first reported a position in Integra LifeSciences in Q2 2016 and held it in 3 quarters.
  • Invictus RG's Integra LifeSciences position peaked at $14K in Q4 2016.
  • 236 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2017.

Based on Invictus RG's 13F filing for Q1 2017, filed 12 May 2017.